Pheton stock plunges over 90% after Bear Cave warns of manipulation
CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage biotech company with a strong balance sheet showing more cash than debt and a current market capitalization of $85 million, announced Tuesday positive interim data from its Phase 2a clinical trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients. According to InvestingPro data, the company maintains a healthy current ratio of 7.48, indicating strong short-term financial stability.
The trial showed 94% overall survival and 72% progression-free survival at six months for patients receiving the 320 mg once-daily dose of atebimetinib combined with mGnP. According to the company, these rates compare favorably to standard care benchmarks of 67% and 44%, respectively. Median overall survival and progression-free survival had not been reached as of the May 26 data cutoff. The positive trial results have contributed to the stock’s impressive performance, with InvestingPro data showing a 54% return over the past year and a 37% gain in the last six months.
The treatment demonstrated a 39% overall response rate and 81% disease control rate across both the 240 mg and 320 mg dose levels, with multiple patients experiencing tumor regression.
Immuneering reported that atebimetinib showed a favorable tolerability profile when combined with chemotherapy, with no Grade 3 or higher adverse events observed in most categories typically associated with standard pancreatic cancer treatments.
Based on these results, the company has increased target enrollment in the pancreatic cancer combination arm to approximately 50 patients.
Vincent Chung, Professor at City of Hope and principal investigator of the trial, called the data "encouraging" and noted the potential for "a new and significantly more durable treatment option for pancreatic cancer patients."
Immuneering plans to seek regulatory feedback on pivotal study plans in the fourth quarter of 2025, with additional Phase 2a data expected in the same period. The company aims to initiate a pivotal randomized trial of the combination in first-line pancreatic cancer in 2026.
The oral MEK inhibitor is designed to improve durability and tolerability for patients with MAPK pathway-driven tumors, including most pancreatic cancers.
This information is based on a company press release statement. While the clinical results appear promising, InvestingPro analysis indicates the company is currently burning through cash rapidly, with analysts not anticipating profitability this year. InvestingPro subscribers have access to 13 additional key insights about IMRX, including detailed financial health metrics and future growth projections.
In other recent news, Immuneering Corporation held its Annual Meeting of Stockholders, where three Class I directors were elected, and the appointment of RSM US LLP as the company’s independent registered public accounting firm was ratified. Ann E. Berman, Diana F. Hausman, M.D., and Thomas J. Schall, Ph.D. were elected to serve until the 2028 Annual Meeting. Additionally, Immuneering has appointed Dr. Igor Matushansky as its new Chief Medical Officer. Dr. Matushansky will lead the clinical strategies for Immuneering’s cancer drug programs, including the ongoing Phase 2a trial of IMM-1-104, aimed at treating pancreatic cancer. The company plans to present updated data from this trial in the second quarter of 2025. Dr. Matushansky brings extensive experience, having previously served in leadership roles at Sail Biomedicines and Ipsen Pharmaceuticals. His appointment is seen as a strategic move to enhance the development of Immuneering’s cancer therapies. These developments reflect Immuneering’s ongoing efforts to advance its pipeline of cancer treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.